Takeda Collaborates with Enzyre to Develop Diagnostic Device to Regulate Coagulation Status in Patients with Hemophilia at Home

Shots:

• Enzyre to receive funding to advance its existing technology for the development of the diagnostic device, allowing hemophilia patients to automatically determine their coagulation status at home and transfer test results to HCPs via app
• The focus of the collaboration is to deliver patient-centric, personalized healthcare to patients and to advance SOC of patients with bleeding disorders
• Enzyre’s technology is a small single-use diagnostic tool that requires a small volume of blood and is able to measure ~12 reactions simultaneously with high sensitivity and specificity, providing benefits to patients by avoiding crisis occurs by changing coagulation status, reduces GP consultation visits, thus optimizing treatment for the patients

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Takeda, Enzyre